Up-regulation of MHC class I and class II in the skeletal muscles of myasthenia gravis

Journal of Neuroimmunology

Volumn 225, Issue 1-2, 2010, Pages 171-174

  Iwasa, Kazuo ^a   Kato Motozaki, Yuko ^a   Furukawa, Yutaka ^a   Maruta, Takahiro ^a   Ishida, Chiho ^b   Yoshikawa, Hiroaki ^a,c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

MHC; Myasthenia gravis; Skeletal muscle

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SKELETAL MUSCLE; THYMECTOMY; THYMOMA; UPREGULATION;

ADOLESCENT; ADULT; ANTIGENS, CD45; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A ANTIGENS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THYMOMA; UP-REGULATION; YOUNG ADULT;

EID: 77955664057     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.04.017     Document Type: Article

References (19)

1. Avni I., Sharabi Y., Sadeh M., Buchman A.S. Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. Muscle Nerve 2006, 34:242-245.
2. Curnow J., Corlett L., Willcox N., Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001, 115:127-134.
3. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum. Pathol. 1989, 20:224-231.
4. Karpati G., Pouliot Y., Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann. Neurol. 1988, 23:64-72.
5. Nagaraju K. Immunological capabilities of skeletal muscle cells. Acta Physiol. Scand. 2001, 171:215-223.
6. Nagaraju K., Raben N., Merritt G., Loeffler L., Kirk K., Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin. Exp. Immunol. 1998, 113:407-414.
7. Nagaraju K., Casciola-Rosen L., Lundberg I., Rawat R., Cutting S., Thapliyal R., Chang J., Dwivedi S., Mitsak M., Chen Y.W., Plotz P., Rosen A., Hoffman E., Raben N. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005, 52:1824-1835.
8. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172.
9. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 2007, 17:194-200.
10. Otton S.H., Standen G.R., Ormerod I.E. T cell lymphocytosis associated with polymyositis, myasthenia gravis and thymoma. Clin. Lab. Haematol. 2000, 22:307-308.
11. Raschilas F., Mouthon L., Andre M.H., Azorin J., Couvelard A., Guillevin L. Concomitant polymyositis and myasthenia gravis reveal malignant thymoma. A case report and review of the literature. Ann Med Interne 1999, 150:370-373. (Paris).
12. Romi F., Skeie G.O., Gilhus N.E., Aarli J.A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch. Neurol. 2005, 62:442-446.
13. Skeie G.O., Romi F., Aarli J.A., Bentsen P.T., Gilhus N.E. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Ann. N. Y. Acad. Sci. 2003, 998:343-350.
14. Takamori M., Motomura M., Kawaguchi N., Nemoto Y., Hattori T., Yoshikawa H., Otsuka K. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004, 62:1894-1896.
15. Tanahashi N., Sato H., Nogawa S., Satoh T., Kawamura M., Shimoda M. A case report of giant cell myocarditis and myositis observed during the clinical course of invasive thymoma associated with myasthenia gravis. Keio J. Med. 2004, 53:30-42.
16. van der Pas J., Hengstman G.J., ter Laak H.J., Borm G.F., van Engelen B.G. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004, 75:136-139.
17. Wiendl H., Lautwein A., Mitsdorffer M., Krause S., Erfurth S., Wienhold W., Morgalla M., Weber E., Overkleeft H.S., Lochmuller H., Melms A., Tolosa E., Driessen C. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol 2003, 138:132-143.
18. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005, 26:373-380.
19. Zamecnik J., Vesely D., Jakubicka B., Simkova L., Pitha J., Schutzner J., Mazanec R., Vogel H. Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis. Neuromuscul. Disord. 2007, 17:935-942.